TY - JOUR
T1 - Tetracycline-inactivating enzymes
AU - Markley, Jana L.
AU - Wencewicz, Timothy A.
N1 - Funding Information:
A special acknowledgment is given to the tetracycline destructase research team at Washington University in St. Louis including Prof. Gautam Dantas (School of Medicine), Prof. Niraj Tolia (School of Medicine), Prof. Timothy Wencewicz (Department of Chemistry), Dr. Kevin Forsberg (Dantas Lab; currently at Fred Hutch Cancer Research Center), Dr. Jooyoung Park (Tolia Lab; currently at University of Washington), Dr. Jana Markley (Wencewicz Lab), Dr. Hirdesh Kumar (Tolia Lab), Dr. Jie Sun (Dantas Lab; currently at North Carolina State University), Andrew Gasparrini (Dantas Lab), Margaret Reck (Wencewicz Lab; currently at Carboline, St. Louis, MO, United States), Chanez Symister (Wencewicz Lab), Luting Fang (Wencewicz Lab), and Tayte Campbell (Dantas Lab). TW and JM acknowledge the National Institute of Allergy and Infectious Diseases, National Institutes of Health, grant R01 123394 for supporting our work on tetracycline-inactivating enzymes.
Publisher Copyright:
© 2018 Markley and Wencewicz.
PY - 2018/5/30
Y1 - 2018/5/30
N2 - Tetracyclines have been foundational antibacterial agents for more than 70 years. Renewed interest in tetracycline antibiotics is being driven by advancements in tetracycline synthesis and strategic scaffold modifications designed to overcome established clinical resistance mechanisms including efflux and ribosome protection. Emerging new resistance mechanisms, including enzymatic antibiotic inactivation, threaten recent progress on bringing these next-generation tetracyclines to the clinic. Here we review the current state of knowledge on the structure, mechanism, and inhibition of tetracycline-inactivating enzymes.
AB - Tetracyclines have been foundational antibacterial agents for more than 70 years. Renewed interest in tetracycline antibiotics is being driven by advancements in tetracycline synthesis and strategic scaffold modifications designed to overcome established clinical resistance mechanisms including efflux and ribosome protection. Emerging new resistance mechanisms, including enzymatic antibiotic inactivation, threaten recent progress on bringing these next-generation tetracyclines to the clinic. Here we review the current state of knowledge on the structure, mechanism, and inhibition of tetracycline-inactivating enzymes.
KW - Antibiotic adjuvants
KW - Antibiotic resistance
KW - Enzymatic antibiotic inactivation
KW - Flavin monooxygenase
KW - Tetracycline destructases
KW - Tetracyclines
UR - https://www.scopus.com/pages/publications/85047809222
U2 - 10.3389/fmicb.2018.01058
DO - 10.3389/fmicb.2018.01058
M3 - Review article
AN - SCOPUS:85047809222
SN - 1664-302X
VL - 9
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
IS - MAY
M1 - 1058
ER -